Canaccord lowered the firm’s price target on Cibus to $21 from $22 and keeps a Buy rating on the shares. The firm noted they reported its Q2/24 results highlighting continued progress in its transition from being R&D focused to becoming the first commercial-stage gene editing company in the AgTech industry.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBUS:
- Cibus reports Q2 EPS (81c), consensus ($1.14)
- Cibus announces ‘positive’ initial field test results of novel weed management
- Cibus Achieves Positive Initial Field Trial Results for Stacked Gene Edited Herbicide Tolerant Traits in Rice
- Cibus to Report Second Quarter 2024 Financial Results on August 8, 2024 After the Market Close and Host Conference Call
- Cibus initiated with a Buy at Alliance Global Partners